FTC Settlement May Portend Antitrust Scrutiny Of ANDA First-Filer Deals

The Federal Trade Commission's settlement with Perrigo and Alpharma suggests that deals struck between competing first-to-file generic drug manufacturers may trigger future antitrust scrutiny